The Klinique Med Clinic PCL (KLINIQ) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of The Klinique Med Clinic PCL stock THB 35.20, price THB 32.00, upside +10.0%, quality 72 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
48‑month range 18.70 THB – 39.45 THB · fair‑value band 24.81 THB – 50.33 THB · the 32.00 THB price screens below the 35.20 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow The Klinique Med Clinic PCL in your weekly email
Every Wednesday you see whether The Klinique Med Clinic PCL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
The Klinique Medical Clinic Public Company Limited provides skin medical treatment services under the Klinique brand name in Thailand.
Show moreShow less
Its services include face lift, acne, pimples, and acne scars, skin tightening, filler, fat dissolving injection, laser hair removal, skin treatment, skin injection, mesofront, mesotherapy, and rhinoplasty, as well as nose, eye, and facial surgery.
The company also offers skin medical services and distribution of cosmetics and medical cosmetics, and surgery services. The Klinique Medical Clinic Public Company Limited was founded in 2009 and is based in Bangkok, Thailand.
Stock analysis
The Klinique Med Clinic PCL (KLINIQ) currently trades at 32.00 THB, while our model-based Fair Value estimate is 35.20 THB, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 52.70 THB per share, and 15 of the 26 models we run sit above the 32.00 THB price.
Bear case: the Asset-Based group reads lowest at 5.39 THB, and 11 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 24.81 THB (bear) to 50.33 THB (bull), the price of 32.00 THB sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Consumer Cyclical sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
The Klinique Med Clinic PCL reported revenue of 3.6B THB in FY2025 versus 950M THB in FY2021, a compound +39.1%/yr. Reported net income was 364M THB in FY2025, compounding +29.5%/yr from FY2021.
Key figures
Market cap 7.0B THB (≈ $210M) Micro · P/E ratio 17.1 · P/S ratio 1.72 · EPS (TTM) 1.87 THB · Dividend yield 5.1% · Net margin 10.3% · Return on equity 23.5% · Return on assets (EBIT) 13.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 63 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 71% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at 4% fair-value upside, at 10%, KLINIQ screens cheaper than that median.
Fair Value models
Bear24.81 THBFair Value 35.20 THBBull50.33 THB
Price 32.00 THB · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.2058 THB per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.9%
Start year 2020 (pandemic). Over 10 years: +18.5% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.2%
’13
’14
’15
’16
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+28.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.0%
Dividend (yield on the price)5.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.0% vs −7.3%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 13.1%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+16.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (Thailand: IMF forecast 1.2% a year to 2030, 1.1% from 2016 to 2025) that is about +12.8% a year for the price and +15.4% for the forecasts.
Compare The Klinique Med Clinic PCL with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Personal Services · 38 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside+10.0% · Below median
Profitability
Return on equity (12 months)23.5% · Above median
Return on assets10.5% · Top 25%
Net margin (12 months)10.3% · Above median
Operating margin (12 months)13.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)32.4% · Top 25%
Dividend yield (12 months)5.1% · Above median
Valuation Multiplesvs Personal Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "The Klinique Med Clinic PCL Fair Value". https://www.fairvalue-calculator.com/stock/KLINIQ
Frequently asked questions
Is The Klinique Med Clinic PCL (KLINIQ) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 35.20 THB versus a price of 32.00 THB, about +10% upside (fairly valued).
What is the fair value of KLINIQ?
Our model-based fair value for The Klinique Med Clinic PCL is 35.20 THB (as of Nov 8, 2026), built from audited fundamentals. The current price: 32.00 THB.
What is the quality score of KLINIQ?
The Klinique Med Clinic PCL has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for The Klinique Med Clinic PCL (KLINIQ)?
Our model-based price target is the fair value of 35.20 THB (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 24.81 THB, optimistic scenario 50.33 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the The Klinique Med Clinic PCL stock forecast for 2026?
Our models put fair value at 35.20 THB, about +10% upside versus a price of 32.00 THB (fairly valued). Cautious scenario 24.81 THB, optimistic scenario 50.33 THB. The calculation is refreshed regularly with new filings.
What is the revenue of The Klinique Med Clinic PCL (KLINIQ)?
The Klinique Med Clinic PCL reported trailing-twelve-month revenue of about 4.1B THB (latest available figure, as of Nov 8, 2026).
Does The Klinique Med Clinic PCL pay a dividend?
The Klinique Med Clinic PCL currently shows a dividend yield of 5.09% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of The Klinique Med Clinic PCL (KLINIQ) and when is the ex-dividend date?
The Klinique Med Clinic PCL pays a dividend of 1.63 THB per share a year, a dividend yield of 5.1%. The last ex-dividend date was Aug 27, 2026. The payout ratio is 87.2% of earnings. Free cash flow covers the dividend 1.04 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into The Klinique Med Clinic PCL (KLINIQ)?
For today's price to be fair in a discounted-cash-flow model, The Klinique Med Clinic PCL would have to grow free cash flow by +14.2 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +28.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of KLINIQ use?
Our models discount The Klinique Med Clinic PCL at 13.1 %: a base by market capitalisation (micro), damped by beta 0.36, country premium for Thailand. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For The Klinique Med Clinic PCL that is +14.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has The Klinique Med Clinic PCL (KLINIQ) delivered so far?
Over the past 5 years revenue at The Klinique Med Clinic PCL grew +28.9 % a year. The price currently implies free-cash-flow growth of +14.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of The Klinique Med Clinic PCL (KLINIQ) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into The Klinique Med Clinic PCL (+14.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of The Klinique Med Clinic PCL (KLINIQ)?
The free-cash-flow yield on the price is 5.27 %: that much free cash flow The Klinique Med Clinic PCL produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of The Klinique Med Clinic PCL (KLINIQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For The Klinique Med Clinic PCL it is 35.20 THB per share (as of Nov 8, 2026), against a price of 32.00 THB. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is The Klinique Med Clinic PCL stock overvalued or undervalued in 2026?
As of Nov 8, 2026, KLINIQ trades below its calculated fair value: price 32.00 THB, fair value 35.20 THB, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KLINIQ?
No. The price is what the market pays today (32.00 THB); the fair value is what the company's own numbers justify (35.20 THB). For The Klinique Med Clinic PCL the two are 3.20 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is The Klinique Med Clinic PCL worth?
The market values The Klinique Med Clinic PCL at about 7.0B THB (market capitalisation, as of Nov 8, 2026). Per share that is 32.00 THB; our models calculate a fair value of 35.20 THB per share.
What do the bullish and bearish scenarios say about KLINIQ?
Our models span a range for The Klinique Med Clinic PCL: cautious scenario 24.81 THB, base 35.20 THB, optimistic 50.33 THB per share (as of Nov 8, 2026, price 32.00 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KLINIQ?
The Klinique Med Clinic PCL trades at a price-to-earnings ratio of 17.1 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 35.20 THB is built from several models across several years. Other multiples: PEG 0.6, P/B 4.0, P/S 1.7, EV/EBITDA 9.8.
What is the PEG ratio of KLINIQ?
The PEG ratio of The Klinique Med Clinic PCL is 0.62 (P/E divided by earnings growth, as of Nov 8, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of The Klinique Med Clinic PCL (KLINIQ)?
Balance-sheet figures for The Klinique Med Clinic PCL (as of Nov 8, 2026): return on equity 23.5%. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is KLINIQ from its 52-week high?
The Klinique Med Clinic PCL trades at 32.00 THB, about 4% below its 52-week high of 33.50 THB and 71% above the low of 18.70 THB (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 35.20 THB is for.
Which stocks are comparable to The Klinique Med Clinic PCL?
From the same area (Consumer Cyclical) we also value Rollins, Inc, Service Corporation, Frontdoor, Inc, H&R Block, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is The Klinique Med Clinic PCL stock attractive at the current price?
The data as of Nov 8, 2026: price 32.00 THB, calculated fair value 35.20 THB (+10%), Quality Score 72/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KLINIQ calculated?
We run The Klinique Med Clinic PCL through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 35.20 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. The Klinique Med Clinic PCL currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of The Klinique Med Clinic PCL (KLINIQ)?
The closing price on Nov 6, 2026 was 32.00 THB. Our model-based fair value is 35.20 THB, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with The Klinique Med Clinic PCL right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (24.81 THB to 50.33 THB) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of The Klinique Med Clinic PCL (KLINIQ) come from?
Earnings per share at The Klinique Med Clinic PCL grew +7.8 % a year from 2015 to 2025. Broken into its drivers: revenue per share +2.9 %, EBIT margin +4.8 %, tax rate −0.1 %, residual (interest, one-offs) +0.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of The Klinique Med Clinic PCL
How large is the market capitalisation of The Klinique Med Clinic PCL (KLINIQ)?
The market capitalisation of The Klinique Med Clinic PCL is 7.0B THB (≈ $210M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of The Klinique Med Clinic PCL (KLINIQ)?
The price-to-sales ratio of The Klinique Med Clinic PCL is 1.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of The Klinique Med Clinic PCL (KLINIQ)?
Earnings per share at The Klinique Med Clinic PCL are 1.87 THB (price ÷ EPS = P/E 17.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of The Klinique Med Clinic PCL (KLINIQ)?
The dividend yield of The Klinique Med Clinic PCL is 5.1% (payout 87.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of The Klinique Med Clinic PCL (KLINIQ)?
The net margin of The Klinique Med Clinic PCL is 10.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of The Klinique Med Clinic PCL (KLINIQ)?
The return on equity (ROE) of The Klinique Med Clinic PCL is 23.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of The Klinique Med Clinic PCL (KLINIQ)?
On an EBIT basis the return on assets of The Klinique Med Clinic PCL is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of The Klinique Med Clinic PCL (KLINIQ)?
The operating margin of The Klinique Med Clinic PCL is 13.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at The Klinique Med Clinic PCL (KLINIQ)?
Revenue at The Klinique Med Clinic PCL is growing +32.4% versus a year earlier (3y avg +29.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at The Klinique Med Clinic PCL (KLINIQ)?
Earnings per share at The Klinique Med Clinic PCL are growing +24.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does The Klinique Med Clinic PCL (KLINIQ) carry?
The net debt of The Klinique Med Clinic PCL is 909M THB (fiscal year 2025, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch The Klinique Med Clinic PCL in the live analysis
One click puts The Klinique Med Clinic PCL on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026